Literature DB >> 19000665

Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.

Benjamin Dieplinger1, Alfons Gegenhuber, Joachim Struck, Werner Poelz, Werner Langsteger, Meinhard Haltmayer, Thomas Mueller.   

Abstract

BACKGROUND: The aim of this study was to evaluate the prognostic value of chromogranin A (CgA) and C-terminal endothelin-1 precursor fragment (CT-proET-1) in patients with acute destabilized heart failure.
METHODS: 137 consecutive patients with acute destabilized heart failure attending the emergency department of a tertiary care hospital were prospectively enrolled. Plasma concentrations of CgA, CT-proET-1, and amino-terminal proBNP (NT-proBNP) were measured at baseline. The endpoint was defined as all-cause mortality; the study participants were followed up for 365 days.
RESULTS: Decedents (n=41) had higher median plasma concentrations of CgA (9.7 vs. 6.0 nmol/L; p=0.002), CT-proET-1 (120 vs. 72 pmol/L; p=0.006), and NT-proBNP (5112 vs. 2610 ng/L; p<0.001) at baseline than survivors (n=96). Applying Cox proportional-hazards regression analyses, increased CgA (>6.6 nmol/L), CT-proET-1 (>79 pmol/L), and NT-proBNP (>3275 ng/L) revealed significant risk ratios of 1.96 (95% CI, 1.04-3.70) for CgA, 2.56 (95% CI, 1.33-4.95) for CT-proET-1, and 2.05 (95% CI, 1.09-3.87) for NT-proBNP. When the cohort was stratified according to median CgA and NT-proBNP concentrations, and to median CT-proET-1 and NT-proBNP concentrations, respectively, Cox proportional-hazards regression analyses showed the highest risk for death in patients with both increased CgA and NT-proBNP (risk ratio, 3.65; 95% CI, 1.44-9.28), and increased CT-proET-1 and NT-proBNP (risk ratio, 4.03; 95% CI, 1.61-8.88).
CONCLUSIONS: Our study demonstrates that increased CgA and CT-proET-1 plasma concentrations at the initial presentation of patients with acute destabilized heart failure in the emergency department add independent prognostic information in addition to NT-proBNP measurement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000665     DOI: 10.1016/j.cca.2008.10.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  14 in total

Review 1.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

Review 2.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

Review 3.  Novel biomarkers in acute heart failure.

Authors:  Marat Yanavitski; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2011-09

4.  Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction.

Authors:  Stephen S Gottlieb; Kristie Harris; John Todd; Joel Estis; Robert H Christenson; Victoria Torres; Kerry Whittaker; Heather Rebuck; Andrew Wawrzyniak; David S Krantz
Journal:  Clin Biochem       Date:  2014-12-23       Impact factor: 3.281

5.  Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study.

Authors:  Helge Røsjø; Ståle Nygård; Kirsi-Maija Kaukonen; Sari Karlsson; Mats Stridsberg; Esko Ruokonen; Ville Pettilä; Torbjørn Omland
Journal:  Intensive Care Med       Date:  2012-04-11       Impact factor: 17.440

6.  Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.

Authors:  Elisabetta Ferrero; Angelo Corti; Julien Haroche; Daniela Belloni; Barbara Colombo; Alvise Berti; Giulio Cavalli; Corrado Campochiaro; Antonello Villa; Fleur Cohen-Aubart; Zahir Amoura; Claudio Doglioni; Lorenzo Dagna; Marina Ferrarini
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 7.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

8.  Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)).

Authors:  Nilima Biswas; Erica Curello; Daniel T O'Connor; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2010-11-05       Impact factor: 5.249

9.  Prognostic value of circulating chromogranin A levels in acute coronary syndrome.

Authors:  Wojciech Jeske; Piotr Glinicki
Journal:  Eur Heart J       Date:  2009-11-11       Impact factor: 29.983

10.  Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management.

Authors:  Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier
Journal:  Biomark Insights       Date:  2013-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.